To the full analysis
Cytokinetics stock: growth
CYTKCytokinetics reported $88.04M in revenue for fiscal 2025, up 376.6% on the prior year, up 9.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
19.2%
per year from 2006 to 2025, per share 1.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.5% | 11.9% | 19.2% |
| Revenue per share | −3.2% | −0.1% | 1.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.13M | −$57.12M | −$52.54M |
| 2007 | $13.62M | −$48.89M | −$5.57M |
| 2008 | $12.42M | −$56.37M | −$61.99M |
| 2009 | $81.54M | $24.54M | $7.87M |
| 2010 | $2.58M | −$49.29M | −$45.32M |
| 2011 | $4M | −$47.86M | −$46.04M |
| 2012 | $7.56M | −$41.68M | −$33.56M |
| 2013 | $30.65M | −$33.72M | −$8.26M |
| 2014 | $46.94M | −$14.65M | −$45.95M |
| 2015 | $28.66M | −$37.5M | $4.32M |
| 2016 | $106.41M | $16.45M | $35.39M |
| 2017 | $13.37M | −$127.79M | −$104.64M |
| 2018 | $31.5M | −$106.29M | −$102.1M |
| 2019 | $26.87M | −$121.69M | −$93.53M |
| 2020 | $55.83M | −$127.29M | −$2.11M |
| 2021 | $70.43M | −$215.31M | −$191.39M |
| 2022 | $94.59M | −$388.96M | −$310.85M |
| 2023 | $7.53M | −$526.24M | −$415.75M |
| 2024 | $18.47M | −$589.53M | −$399.8M |
| 2025 | $88.04M | −$784.96M | −$534.82M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.